Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Toho Becomes a Major Shareholder of a Generic Maker
September 1, 2008
- Accused Surgeon Found Not Guilty by District Court
September 1, 2008
- Korosho to Demand Budget to Increase PMDA Staff Responsible for Safety Measures by 100
September 1, 2008
- JCR to Request Application for Higher Doses of MTX Based on Public Knowledge
September 1, 2008
- Yamato HD to Introduce New Direct Delivery System for Generics
September 1, 2008
- Doctors' Awareness Needs to Be Renovated to Popularize Biologics for RA
September 1, 2008
- Statistics／Drug Sales Up 0.7% in June: Crecon R&C
September 1, 2008
- 13th ACCJ Media Lectures
August 25, 2008
- Bayer, FUJIFILM RI Pharma Start Receiving Orders on Zevalin
August 25, 2008
- Market Price Surveys to Focus on Generics
August 25, 2008
- Pfizer Starts Detailing Macugen for AMD
August 25, 2008
- R&D NEWS IN BRIEF
August 25, 2008
- Top Management Changes Made within 2 Months Announced by Ono
August 25, 2008
- Development of New Drugs for AMD Stimulated
August 25, 2008
- Eisai Licenses Bendamustine from SymBio
August 25, 2008
- Long Lifecycles Prevent Quick Development of New Drugs in Japan: OPIR Report
August 25, 2008
- Eisai to Apply for 3 Anticancer Drugs by FY2012
August 25, 2008
- REGULATORY NEWS IN BRIEF
August 25, 2008
- DSP to Place Top Priority on Lurasidone: New President Tada
August 25, 2008
- Korosho Opposed to Reference Price System
August 25, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…